nodes	percent_of_prediction	percent_of_DWPC	metapath
Tazarotene—CYP2C8—Trimethadione—epilepsy syndrome	0.109	0.17	CbGbCtD
Tazarotene—CYP2C8—Fosphenytoin—epilepsy syndrome	0.102	0.16	CbGbCtD
Tazarotene—CYP2C8—Carbamazepine—epilepsy syndrome	0.0735	0.115	CbGbCtD
Tazarotene—CYP2C8—Primidone—epilepsy syndrome	0.0686	0.107	CbGbCtD
Tazarotene—CYP2C8—Phenytoin—epilepsy syndrome	0.0659	0.103	CbGbCtD
Tazarotene—CYP2C8—Propofol—epilepsy syndrome	0.0615	0.0962	CbGbCtD
Tazarotene—CYP2C8—Phenobarbital—epilepsy syndrome	0.0588	0.092	CbGbCtD
Tazarotene—CYP2C8—Diazepam—epilepsy syndrome	0.0557	0.0872	CbGbCtD
Tazarotene—CYP2C8—Valproic Acid—epilepsy syndrome	0.0439	0.0687	CbGbCtD
Tazarotene—Impetigo—Oxcarbazepine—epilepsy syndrome	0.0134	0.0585	CcSEcCtD
Tazarotene—Localised oedema—Phenobarbital—epilepsy syndrome	0.0103	0.0446	CcSEcCtD
Tazarotene—Facial pain—Lamotrigine—epilepsy syndrome	0.00991	0.0431	CcSEcCtD
Tazarotene—RARG—tongue—epilepsy syndrome	0.0072	0.167	CbGeAlD
Tazarotene—Instillation site pain—Midazolam—epilepsy syndrome	0.00576	0.0251	CcSEcCtD
Tazarotene—Application site pain—Midazolam—epilepsy syndrome	0.00427	0.0186	CcSEcCtD
Tazarotene—Blister—Phenobarbital—epilepsy syndrome	0.0036	0.0156	CcSEcCtD
Tazarotene—Leukoderma—Lamotrigine—epilepsy syndrome	0.00338	0.0147	CcSEcCtD
Tazarotene—RXRB—telencephalon—epilepsy syndrome	0.00316	0.0734	CbGeAlD
Tazarotene—Acne—Rufinamide—epilepsy syndrome	0.00302	0.0132	CcSEcCtD
Tazarotene—RARA—telencephalon—epilepsy syndrome	0.00264	0.0613	CbGeAlD
Tazarotene—Cheilitis—Pregabalin—epilepsy syndrome	0.00243	0.0106	CcSEcCtD
Tazarotene—Stinging—Propofol—epilepsy syndrome	0.00237	0.0103	CcSEcCtD
Tazarotene—Blood triglycerides increased—Carbamazepine—epilepsy syndrome	0.00227	0.00987	CcSEcCtD
Tazarotene—Cheilitis—Gabapentin—epilepsy syndrome	0.00223	0.00969	CcSEcCtD
Tazarotene—RARB—head—epilepsy syndrome	0.00214	0.0497	CbGeAlD
Tazarotene—Acne—Vigabatrin—epilepsy syndrome	0.00207	0.00902	CcSEcCtD
Tazarotene—Blister—Carbamazepine—epilepsy syndrome	0.00206	0.00897	CcSEcCtD
Tazarotene—Skin discolouration—Levetiracetam—epilepsy syndrome	0.00205	0.00893	CcSEcCtD
Tazarotene—Skin discolouration—Fosphenytoin—epilepsy syndrome	0.00198	0.00862	CcSEcCtD
Tazarotene—Acne—Felbamate—epilepsy syndrome	0.00198	0.00859	CcSEcCtD
Tazarotene—RXRB—head—epilepsy syndrome	0.00197	0.0457	CbGeAlD
Tazarotene—Dermatitis bullous—Phenobarbital—epilepsy syndrome	0.00197	0.00856	CcSEcCtD
Tazarotene—RARB—cerebellum—epilepsy syndrome	0.00191	0.0444	CbGeAlD
Tazarotene—Skin discolouration—Diazepam—epilepsy syndrome	0.0019	0.00827	CcSEcCtD
Tazarotene—RXRB—nervous system—epilepsy syndrome	0.00187	0.0433	CbGeAlD
Tazarotene—Acne—Oxcarbazepine—epilepsy syndrome	0.00184	0.00801	CcSEcCtD
Tazarotene—RXRB—central nervous system—epilepsy syndrome	0.0018	0.0417	CbGeAlD
Tazarotene—Skin exfoliation—Midazolam—epilepsy syndrome	0.00179	0.0078	CcSEcCtD
Tazarotene—Dermatitis contact—Fosphenytoin—epilepsy syndrome	0.00177	0.00769	CcSEcCtD
Tazarotene—RXRB—cerebellum—epilepsy syndrome	0.00176	0.0408	CbGeAlD
Tazarotene—RARG—head—epilepsy syndrome	0.00175	0.0406	CbGeAlD
Tazarotene—Skin discolouration—Clonazepam—epilepsy syndrome	0.00174	0.00755	CcSEcCtD
Tazarotene—Skin discolouration—Phenytoin—epilepsy syndrome	0.00172	0.0075	CcSEcCtD
Tazarotene—Acne—Lamotrigine—epilepsy syndrome	0.00171	0.00743	CcSEcCtD
Tazarotene—RARG—nervous system—epilepsy syndrome	0.00166	0.0385	CbGeAlD
Tazarotene—Skin discolouration—Carbamazepine—epilepsy syndrome	0.00165	0.00716	CcSEcCtD
Tazarotene—RARA—head—epilepsy syndrome	0.00164	0.0381	CbGeAlD
Tazarotene—Inflammation—Clonazepam—epilepsy syndrome	0.00162	0.00703	CcSEcCtD
Tazarotene—Inflammation—Phenytoin—epilepsy syndrome	0.00161	0.00699	CcSEcCtD
Tazarotene—RARG—central nervous system—epilepsy syndrome	0.0016	0.037	CbGeAlD
Tazarotene—Skin discolouration—Lamotrigine—epilepsy syndrome	0.00159	0.00692	CcSEcCtD
Tazarotene—Blister—Valproic Acid—epilepsy syndrome	0.00158	0.00689	CcSEcCtD
Tazarotene—RARG—cerebellum—epilepsy syndrome	0.00156	0.0362	CbGeAlD
Tazarotene—RARA—nervous system—epilepsy syndrome	0.00156	0.0362	CbGeAlD
Tazarotene—RARB—brain—epilepsy syndrome	0.00155	0.036	CbGeAlD
Tazarotene—Dermatitis contact—Clonazepam—epilepsy syndrome	0.00155	0.00674	CcSEcCtD
Tazarotene—Swelling—Midazolam—epilepsy syndrome	0.00155	0.00672	CcSEcCtD
Tazarotene—Dermatitis contact—Phenytoin—epilepsy syndrome	0.00154	0.0067	CcSEcCtD
Tazarotene—Dermatitis contact—Oxcarbazepine—epilepsy syndrome	0.00153	0.00666	CcSEcCtD
Tazarotene—RARA—central nervous system—epilepsy syndrome	0.0015	0.0348	CbGeAlD
Tazarotene—Eczema—Levetiracetam—epilepsy syndrome	0.0015	0.00652	CcSEcCtD
Tazarotene—Burning sensation—Pregabalin—epilepsy syndrome	0.00149	0.00646	CcSEcCtD
Tazarotene—Haemoglobin—Trimethadione—epilepsy syndrome	0.00148	0.00643	CcSEcCtD
Tazarotene—Haemorrhage—Trimethadione—epilepsy syndrome	0.00147	0.00639	CcSEcCtD
Tazarotene—RARA—cerebellum—epilepsy syndrome	0.00147	0.034	CbGeAlD
Tazarotene—RXRB—brain—epilepsy syndrome	0.00143	0.0331	CbGeAlD
Tazarotene—Dermatitis contact—Lamotrigine—epilepsy syndrome	0.00142	0.00618	CcSEcCtD
Tazarotene—Swelling—Diazepam—epilepsy syndrome	0.00141	0.00615	CcSEcCtD
Tazarotene—Dermatitis bullous—Levetiracetam—epilepsy syndrome	0.00141	0.00613	CcSEcCtD
Tazarotene—Eczema—Zonisamide—epilepsy syndrome	0.00131	0.00572	CcSEcCtD
Tazarotene—Blister—Gabapentin—epilepsy syndrome	0.00131	0.00571	CcSEcCtD
Tazarotene—Swelling—Clonazepam—epilepsy syndrome	0.00129	0.00561	CcSEcCtD
Tazarotene—RARG—brain—epilepsy syndrome	0.00127	0.0294	CbGeAlD
Tazarotene—Dermatitis bullous—Felbamate—epilepsy syndrome	0.00126	0.00549	CcSEcCtD
Tazarotene—Eczema—Oxcarbazepine—epilepsy syndrome	0.00125	0.00544	CcSEcCtD
Tazarotene—Dermatitis bullous—Zonisamide—epilepsy syndrome	0.00124	0.00538	CcSEcCtD
Tazarotene—Swelling—Carbamazepine—epilepsy syndrome	0.00122	0.00532	CcSEcCtD
Tazarotene—RARA—brain—epilepsy syndrome	0.00119	0.0276	CbGeAlD
Tazarotene—Photosensitivity reaction—Acetazolamide—epilepsy syndrome	0.00118	0.00515	CcSEcCtD
Tazarotene—Eczema—Lamotrigine—epilepsy syndrome	0.00116	0.00505	CcSEcCtD
Tazarotene—Burning sensation—Topiramate—epilepsy syndrome	0.00115	0.00499	CcSEcCtD
Tazarotene—Skin discolouration—Pregabalin—epilepsy syndrome	0.00114	0.00497	CcSEcCtD
Tazarotene—Erythema—Phenobarbital—epilepsy syndrome	0.00113	0.00493	CcSEcCtD
Tazarotene—Dermatitis bullous—Carbamazepine—epilepsy syndrome	0.00113	0.00491	CcSEcCtD
Tazarotene—Acne—Gabapentin—epilepsy syndrome	0.00113	0.00489	CcSEcCtD
Tazarotene—Dermatitis bullous—Lamotrigine—epilepsy syndrome	0.00109	0.00475	CcSEcCtD
Tazarotene—Dry skin—Zonisamide—epilepsy syndrome	0.00108	0.00471	CcSEcCtD
Tazarotene—Discomfort—Trimethadione—epilepsy syndrome	0.00108	0.00468	CcSEcCtD
Tazarotene—Skin discolouration—Gabapentin—epilepsy syndrome	0.00105	0.00456	CcSEcCtD
Tazarotene—Erythema—Lacosamide—epilepsy syndrome	0.00104	0.00454	CcSEcCtD
Tazarotene—Photosensitivity reaction—Fosphenytoin—epilepsy syndrome	0.00103	0.00446	CcSEcCtD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—epilepsy syndrome	0.001	0.0114	CbGpPWpGaD
Tazarotene—Skin exfoliation—Pregabalin—epilepsy syndrome	0.000986	0.00429	CcSEcCtD
Tazarotene—Photosensitivity reaction—Diazepam—epilepsy syndrome	0.000984	0.00428	CcSEcCtD
Tazarotene—Haemoglobin—Propofol—epilepsy syndrome	0.000969	0.00421	CcSEcCtD
Tazarotene—Haemorrhage—Propofol—epilepsy syndrome	0.000964	0.00419	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors—NR3C1—epilepsy syndrome	0.000959	0.0109	CbGpPWpGaD
Tazarotene—Dry skin—Lamotrigine—epilepsy syndrome	0.000956	0.00416	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—VDR—epilepsy syndrome	0.000955	0.0109	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Felbamate—epilepsy syndrome	0.000952	0.00414	CcSEcCtD
Tazarotene—Acne—Topiramate—epilepsy syndrome	0.000947	0.00412	CcSEcCtD
Tazarotene—Swelling—Valproic Acid—epilepsy syndrome	0.00094	0.00409	CcSEcCtD
Tazarotene—CYP2C8—CYP2E1 reactions—CYP2C19—epilepsy syndrome	0.000924	0.0105	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—VDR—epilepsy syndrome	0.000916	0.0104	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—VDR—epilepsy syndrome	0.000916	0.0104	CbGpPWpGaD
Tazarotene—Skin exfoliation—Gabapentin—epilepsy syndrome	0.000904	0.00393	CcSEcCtD
Tazarotene—Photosensitivity reaction—Phenytoin—epilepsy syndrome	0.000892	0.00388	CcSEcCtD
Tazarotene—Photosensitivity reaction—Oxcarbazepine—epilepsy syndrome	0.000887	0.00386	CcSEcCtD
Tazarotene—Skin discolouration—Topiramate—epilepsy syndrome	0.000882	0.00384	CcSEcCtD
Tazarotene—Discomfort—Lacosamide—epilepsy syndrome	0.000879	0.00382	CcSEcCtD
Tazarotene—Dermatitis bullous—Valproic Acid—epilepsy syndrome	0.000867	0.00377	CcSEcCtD
Tazarotene—Oedema peripheral—Vigabatrin—epilepsy syndrome	0.000863	0.00375	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—NR3C1—epilepsy syndrome	0.00086	0.00978	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Carbamazepine—epilepsy syndrome	0.000852	0.0037	CcSEcCtD
Tazarotene—Oedema peripheral—Diazepam—epilepsy syndrome	0.00085	0.0037	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—VDR—epilepsy syndrome	0.000842	0.00957	CbGpPWpGaD
Tazarotene—Erythema—Propofol—epilepsy syndrome	0.000839	0.00365	CcSEcCtD
Tazarotene—Haemoglobin—Felbamate—epilepsy syndrome	0.000839	0.00365	CcSEcCtD
Tazarotene—Haemorrhage—Felbamate—epilepsy syndrome	0.000835	0.00363	CcSEcCtD
Tazarotene—Eczema—Pregabalin—epilepsy syndrome	0.000834	0.00363	CcSEcCtD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—BCL2—epilepsy syndrome	0.000833	0.00947	CbGpPWpGaD
Tazarotene—CYP2C8—CYP2E1 reactions—CYP2D6—epilepsy syndrome	0.000829	0.00942	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—NR3C1—epilepsy syndrome	0.000824	0.00937	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—NR3C1—epilepsy syndrome	0.000824	0.00937	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Lamotrigine—epilepsy syndrome	0.000823	0.00358	CcSEcCtD
Tazarotene—RARA—Adipogenesis—MIF—epilepsy syndrome	0.000821	0.00934	CbGpPWpGaD
Tazarotene—Erythema—Midazolam—epilepsy syndrome	0.000821	0.00357	CcSEcCtD
Tazarotene—Oedema peripheral—Zonisamide—epilepsy syndrome	0.000805	0.0035	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—NTF3—epilepsy syndrome	0.000802	0.00912	CbGpPWpGaD
Tazarotene—Haemoglobin—Clonazepam—epilepsy syndrome	0.000792	0.00344	CcSEcCtD
Tazarotene—Pain—Phenobarbital—epilepsy syndrome	0.000791	0.00344	CcSEcCtD
Tazarotene—Haemorrhage—Clonazepam—epilepsy syndrome	0.000788	0.00343	CcSEcCtD
Tazarotene—Haemoglobin—Phenytoin—epilepsy syndrome	0.000786	0.00342	CcSEcCtD
Tazarotene—Dermatitis bullous—Pregabalin—epilepsy syndrome	0.000784	0.00341	CcSEcCtD
Tazarotene—Haemorrhage—Phenytoin—epilepsy syndrome	0.000782	0.0034	CcSEcCtD
Tazarotene—Swelling—Gabapentin—epilepsy syndrome	0.000779	0.00339	CcSEcCtD
Tazarotene—Rash—Amobarbital—epilepsy syndrome	0.000777	0.00338	CcSEcCtD
Tazarotene—Dermatitis—Amobarbital—epilepsy syndrome	0.000776	0.00338	CcSEcCtD
Tazarotene—Oedema peripheral—Clonazepam—epilepsy syndrome	0.000776	0.00337	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—NTF3—epilepsy syndrome	0.000769	0.00875	CbGpPWpGaD
Tazarotene—Oedema peripheral—Oxcarbazepine—epilepsy syndrome	0.000767	0.00333	CcSEcCtD
Tazarotene—Eczema—Gabapentin—epilepsy syndrome	0.000765	0.00333	CcSEcCtD
Tazarotene—Discomfort—Acetazolamide—epilepsy syndrome	0.00076	0.00331	CcSEcCtD
Tazarotene—Dry skin—Valproic Acid—epilepsy syndrome	0.00076	0.00331	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—NR3C1—epilepsy syndrome	0.000758	0.00861	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptor transcription pathway—VDR—epilepsy syndrome	0.000755	0.00858	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CAPN1—epilepsy syndrome	0.000754	0.00858	CbGpPWpGaD
Tazarotene—Erythema—Diazepam—epilepsy syndrome	0.000751	0.00327	CcSEcCtD
Tazarotene—Rash—Primidone—epilepsy syndrome	0.000748	0.00326	CcSEcCtD
Tazarotene—Dermatitis—Primidone—epilepsy syndrome	0.000748	0.00325	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—BCL2—epilepsy syndrome	0.000747	0.00849	CbGpPWpGaD
Tazarotene—Pruritus—Trimethadione—epilepsy syndrome	0.000739	0.00321	CcSEcCtD
Tazarotene—Oedema peripheral—Carbamazepine—epilepsy syndrome	0.000736	0.0032	CcSEcCtD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—YWHAZ—epilepsy syndrome	0.000732	0.00832	CbGpPWpGaD
Tazarotene—Haemoglobin—Lamotrigine—epilepsy syndrome	0.000725	0.00316	CcSEcCtD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—VDR—epilepsy syndrome	0.000724	0.00823	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—VDR—epilepsy syndrome	0.000724	0.00823	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CAPN1—epilepsy syndrome	0.000723	0.00822	CbGpPWpGaD
Tazarotene—Haemorrhage—Lamotrigine—epilepsy syndrome	0.000722	0.00314	CcSEcCtD
Tazarotene—Dermatitis bullous—Gabapentin—epilepsy syndrome	0.000719	0.00313	CcSEcCtD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—BCL2—epilepsy syndrome	0.000716	0.00814	CbGpPWpGaD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—BCL2—epilepsy syndrome	0.000716	0.00814	CbGpPWpGaD
Tazarotene—RXRB—Regulation of Androgen receptor activity—SIRT1—epilepsy syndrome	0.000712	0.0081	CbGpPWpGaD
Tazarotene—Oedema peripheral—Lamotrigine—epilepsy syndrome	0.000711	0.00309	CcSEcCtD
Tazarotene—Dry skin—Pregabalin—epilepsy syndrome	0.000687	0.00299	CcSEcCtD
Tazarotene—Oedema—Propofol—epilepsy syndrome	0.000685	0.00298	CcSEcCtD
Tazarotene—RARB—Nuclear Receptor transcription pathway—NR3C1—epilepsy syndrome	0.00068	0.00773	CbGpPWpGaD
Tazarotene—Rash—Trimethadione—epilepsy syndrome	0.000658	0.00286	CcSEcCtD
Tazarotene—Discomfort—Fosphenytoin—epilepsy syndrome	0.000658	0.00286	CcSEcCtD
Tazarotene—Dermatitis—Trimethadione—epilepsy syndrome	0.000658	0.00286	CcSEcCtD
Tazarotene—Photosensitivity reaction—Valproic Acid—epilepsy syndrome	0.000654	0.00284	CcSEcCtD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—NR3C1—epilepsy syndrome	0.000652	0.00741	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—NR3C1—epilepsy syndrome	0.000652	0.00741	CbGpPWpGaD
Tazarotene—Erythema—Carbamazepine—epilepsy syndrome	0.00065	0.00283	CcSEcCtD
Tazarotene—Eczema—Topiramate—epilepsy syndrome	0.000643	0.0028	CcSEcCtD
Tazarotene—Pruritus—Rufinamide—epilepsy syndrome	0.000642	0.00279	CcSEcCtD
Tazarotene—Discomfort—Vigabatrin—epilepsy syndrome	0.000642	0.00279	CcSEcCtD
Tazarotene—RXRB—Regulation of Androgen receptor activity—NR3C1—epilepsy syndrome	0.000632	0.00718	CbGpPWpGaD
Tazarotene—Discomfort—Diazepam—epilepsy syndrome	0.000632	0.00275	CcSEcCtD
Tazarotene—Dry skin—Gabapentin—epilepsy syndrome	0.00063	0.00274	CcSEcCtD
Tazarotene—Erythema—Lamotrigine—epilepsy syndrome	0.000628	0.00273	CcSEcCtD
Tazarotene—Oedema—Vigabatrin—epilepsy syndrome	0.000622	0.00271	CcSEcCtD
Tazarotene—Discomfort—Felbamate—epilepsy syndrome	0.000611	0.00266	CcSEcCtD
Tazarotene—Pruritus—Lacosamide—epilepsy syndrome	0.000603	0.00262	CcSEcCtD
Tazarotene—Discomfort—Zonisamide—epilepsy syndrome	0.000598	0.0026	CcSEcCtD
Tazarotene—Oedema—Felbamate—epilepsy syndrome	0.000593	0.00258	CcSEcCtD
Tazarotene—Photosensitivity reaction—Pregabalin—epilepsy syndrome	0.000591	0.00257	CcSEcCtD
Tazarotene—Pain—Propofol—epilepsy syndrome	0.000586	0.00255	CcSEcCtD
Tazarotene—Pruritus—Clobazam—epilepsy syndrome	0.000585	0.00255	CcSEcCtD
Tazarotene—Rash—Phenobarbital—epilepsy syndrome	0.000583	0.00254	CcSEcCtD
Tazarotene—Dermatitis—Phenobarbital—epilepsy syndrome	0.000583	0.00253	CcSEcCtD
Tazarotene—Oedema—Zonisamide—epilepsy syndrome	0.000581	0.00253	CcSEcCtD
Tazarotene—Discomfort—Clonazepam—epilepsy syndrome	0.000577	0.00251	CcSEcCtD
Tazarotene—Haemoglobin—Valproic Acid—epilepsy syndrome	0.000576	0.00251	CcSEcCtD
Tazarotene—Haemorrhage—Valproic Acid—epilepsy syndrome	0.000574	0.00249	CcSEcCtD
Tazarotene—Pain—Midazolam—epilepsy syndrome	0.000573	0.00249	CcSEcCtD
Tazarotene—Discomfort—Phenytoin—epilepsy syndrome	0.000573	0.00249	CcSEcCtD
Tazarotene—CYP2C8—Xenobiotics—CYP2C19—epilepsy syndrome	0.000573	0.00651	CbGpPWpGaD
Tazarotene—Rash—Rufinamide—epilepsy syndrome	0.000572	0.00249	CcSEcCtD
Tazarotene—Dermatitis—Rufinamide—epilepsy syndrome	0.000572	0.00249	CcSEcCtD
Tazarotene—Discomfort—Oxcarbazepine—epilepsy syndrome	0.00057	0.00248	CcSEcCtD
Tazarotene—Pain—Levetiracetam—epilepsy syndrome	0.000566	0.00246	CcSEcCtD
Tazarotene—Oedema peripheral—Valproic Acid—epilepsy syndrome	0.000565	0.00246	CcSEcCtD
Tazarotene—Oedema—Clonazepam—epilepsy syndrome	0.00056	0.00243	CcSEcCtD
Tazarotene—CYP2C8—Tamoxifen metabolism—CYP2C19—epilepsy syndrome	0.000551	0.00626	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—BMP4—epilepsy syndrome	0.00055	0.00625	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Gabapentin—epilepsy syndrome	0.000542	0.00236	CcSEcCtD
Tazarotene—Rash—Lacosamide—epilepsy syndrome	0.000537	0.00234	CcSEcCtD
Tazarotene—Dermatitis—Lacosamide—epilepsy syndrome	0.000537	0.00234	CcSEcCtD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—epilepsy syndrome	0.000534	0.00607	CbGpPWpGaD
Tazarotene—Pain—Vigabatrin—epilepsy syndrome	0.000532	0.00232	CcSEcCtD
Tazarotene—Oedema—Carbamazepine—epilepsy syndrome	0.000531	0.00231	CcSEcCtD
Tazarotene—Discomfort—Lamotrigine—epilepsy syndrome	0.000528	0.0023	CcSEcCtD
Tazarotene—Pain—Diazepam—epilepsy syndrome	0.000524	0.00228	CcSEcCtD
Tazarotene—Rash—Clobazam—epilepsy syndrome	0.000522	0.00227	CcSEcCtD
Tazarotene—Dermatitis—Clobazam—epilepsy syndrome	0.000521	0.00227	CcSEcCtD
Tazarotene—Haemoglobin—Pregabalin—epilepsy syndrome	0.000521	0.00227	CcSEcCtD
Tazarotene—Haemorrhage—Pregabalin—epilepsy syndrome	0.000518	0.00226	CcSEcCtD
Tazarotene—CYP2C8—Xenobiotics—CYP2D6—epilepsy syndrome	0.000514	0.00584	CbGpPWpGaD
Tazarotene—Oedema—Lamotrigine—epilepsy syndrome	0.000513	0.00223	CcSEcCtD
Tazarotene—Oedema peripheral—Pregabalin—epilepsy syndrome	0.000511	0.00222	CcSEcCtD
Tazarotene—Pain—Felbamate—epilepsy syndrome	0.000507	0.00221	CcSEcCtD
Tazarotene—CYP2C8—Tamoxifen metabolism—CYP2D6—epilepsy syndrome	0.000494	0.00561	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—JUND—epilepsy syndrome	0.000486	0.00553	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—EIF2AK2—epilepsy syndrome	0.000486	0.00553	CbGpPWpGaD
Tazarotene—Pruritus—Propofol—epilepsy syndrome	0.000485	0.00211	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—TNF—epilepsy syndrome	0.000479	0.00545	CbGpPWpGaD
Tazarotene—Pain—Clonazepam—epilepsy syndrome	0.000479	0.00208	CcSEcCtD
Tazarotene—Haemorrhage—Gabapentin—epilepsy syndrome	0.000475	0.00207	CcSEcCtD
Tazarotene—Pruritus—Midazolam—epilepsy syndrome	0.000474	0.00206	CcSEcCtD
Tazarotene—Pain—Oxcarbazepine—epilepsy syndrome	0.000473	0.00206	CcSEcCtD
Tazarotene—CYP2C8—brain—epilepsy syndrome	0.000472	0.011	CbGeAlD
Tazarotene—Oedema peripheral—Gabapentin—epilepsy syndrome	0.000468	0.00204	CcSEcCtD
Tazarotene—Pruritus—Levetiracetam—epilepsy syndrome	0.000468	0.00204	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—EIF2AK2—epilepsy syndrome	0.000466	0.0053	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—JUND—epilepsy syndrome	0.000466	0.0053	CbGpPWpGaD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—epilepsy syndrome	0.000459	0.00522	CbGpPWpGaD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—TNF—epilepsy syndrome	0.000459	0.00522	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Topiramate—epilepsy syndrome	0.000456	0.00198	CcSEcCtD
Tazarotene—Pain—Carbamazepine—epilepsy syndrome	0.000454	0.00197	CcSEcCtD
Tazarotene—Pruritus—Fosphenytoin—epilepsy syndrome	0.000452	0.00197	CcSEcCtD
Tazarotene—Pruritus—Vigabatrin—epilepsy syndrome	0.00044	0.00192	CcSEcCtD
Tazarotene—Pain—Lamotrigine—epilepsy syndrome	0.000438	0.00191	CcSEcCtD
Tazarotene—Pruritus—Diazepam—epilepsy syndrome	0.000434	0.00189	CcSEcCtD
Tazarotene—Rash—Propofol—epilepsy syndrome	0.000432	0.00188	CcSEcCtD
Tazarotene—Dermatitis—Propofol—epilepsy syndrome	0.000431	0.00188	CcSEcCtD
Tazarotene—Rash—Midazolam—epilepsy syndrome	0.000422	0.00184	CcSEcCtD
Tazarotene—Dermatitis—Midazolam—epilepsy syndrome	0.000422	0.00184	CcSEcCtD
Tazarotene—Discomfort—Valproic Acid—epilepsy syndrome	0.00042	0.00183	CcSEcCtD
Tazarotene—Pruritus—Felbamate—epilepsy syndrome	0.00042	0.00183	CcSEcCtD
Tazarotene—Rash—Levetiracetam—epilepsy syndrome	0.000417	0.00181	CcSEcCtD
Tazarotene—Dermatitis—Levetiracetam—epilepsy syndrome	0.000417	0.00181	CcSEcCtD
Tazarotene—Erythema—Gabapentin—epilepsy syndrome	0.000414	0.0018	CcSEcCtD
Tazarotene—Pruritus—Zonisamide—epilepsy syndrome	0.000411	0.00179	CcSEcCtD
Tazarotene—Oedema—Valproic Acid—epilepsy syndrome	0.000407	0.00177	CcSEcCtD
Tazarotene—Rash—Fosphenytoin—epilepsy syndrome	0.000403	0.00175	CcSEcCtD
Tazarotene—Dermatitis—Fosphenytoin—epilepsy syndrome	0.000402	0.00175	CcSEcCtD
Tazarotene—Haemoglobin—Topiramate—epilepsy syndrome	0.000402	0.00175	CcSEcCtD
Tazarotene—Haemorrhage—Topiramate—epilepsy syndrome	0.0004	0.00174	CcSEcCtD
Tazarotene—Pruritus—Clonazepam—epilepsy syndrome	0.000396	0.00172	CcSEcCtD
Tazarotene—Oedema peripheral—Topiramate—epilepsy syndrome	0.000394	0.00171	CcSEcCtD
Tazarotene—Pruritus—Phenytoin—epilepsy syndrome	0.000393	0.00171	CcSEcCtD
Tazarotene—Rash—Vigabatrin—epilepsy syndrome	0.000392	0.00171	CcSEcCtD
Tazarotene—Dermatitis—Vigabatrin—epilepsy syndrome	0.000392	0.00171	CcSEcCtD
Tazarotene—Pruritus—Oxcarbazepine—epilepsy syndrome	0.000391	0.0017	CcSEcCtD
Tazarotene—Rash—Diazepam—epilepsy syndrome	0.000386	0.00168	CcSEcCtD
Tazarotene—Dermatitis—Diazepam—epilepsy syndrome	0.000386	0.00168	CcSEcCtD
Tazarotene—Discomfort—Pregabalin—epilepsy syndrome	0.00038	0.00165	CcSEcCtD
Tazarotene—Pruritus—Carbamazepine—epilepsy syndrome	0.000375	0.00163	CcSEcCtD
Tazarotene—Rash—Felbamate—epilepsy syndrome	0.000374	0.00163	CcSEcCtD
Tazarotene—Dermatitis—Felbamate—epilepsy syndrome	0.000374	0.00163	CcSEcCtD
Tazarotene—Oedema—Pregabalin—epilepsy syndrome	0.000368	0.0016	CcSEcCtD
Tazarotene—RARA—Adipogenesis—SOCS3—epilepsy syndrome	0.000367	0.00417	CbGpPWpGaD
Tazarotene—Rash—Zonisamide—epilepsy syndrome	0.000366	0.00159	CcSEcCtD
Tazarotene—Dermatitis—Zonisamide—epilepsy syndrome	0.000366	0.00159	CcSEcCtD
Tazarotene—Pruritus—Lamotrigine—epilepsy syndrome	0.000363	0.00158	CcSEcCtD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—AKT1—epilepsy syndrome	0.000355	0.00403	CbGpPWpGaD
Tazarotene—Rash—Clonazepam—epilepsy syndrome	0.000353	0.00153	CcSEcCtD
Tazarotene—Dermatitis—Clonazepam—epilepsy syndrome	0.000352	0.00153	CcSEcCtD
Tazarotene—Rash—Phenytoin—epilepsy syndrome	0.00035	0.00152	CcSEcCtD
Tazarotene—Dermatitis—Phenytoin—epilepsy syndrome	0.00035	0.00152	CcSEcCtD
Tazarotene—Rash—Oxcarbazepine—epilepsy syndrome	0.000349	0.00152	CcSEcCtD
Tazarotene—Pain—Valproic Acid—epilepsy syndrome	0.000348	0.00152	CcSEcCtD
Tazarotene—Dermatitis—Oxcarbazepine—epilepsy syndrome	0.000348	0.00151	CcSEcCtD
Tazarotene—Erythema—Topiramate—epilepsy syndrome	0.000348	0.00151	CcSEcCtD
Tazarotene—Discomfort—Gabapentin—epilepsy syndrome	0.000348	0.00151	CcSEcCtD
Tazarotene—RXRB—Regulation of Androgen receptor activity—JUN—epilepsy syndrome	0.000347	0.00395	CbGpPWpGaD
Tazarotene—Oedema—Gabapentin—epilepsy syndrome	0.000338	0.00147	CcSEcCtD
Tazarotene—Rash—Carbamazepine—epilepsy syndrome	0.000335	0.00146	CcSEcCtD
Tazarotene—Dermatitis—Carbamazepine—epilepsy syndrome	0.000334	0.00145	CcSEcCtD
Tazarotene—RARG—Gene Expression—WARS—epilepsy syndrome	0.000332	0.00377	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—JUNB—epilepsy syndrome	0.000331	0.00376	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—MEF2C—epilepsy syndrome	0.000324	0.00368	CbGpPWpGaD
Tazarotene—Rash—Lamotrigine—epilepsy syndrome	0.000323	0.00141	CcSEcCtD
Tazarotene—Dermatitis—Lamotrigine—epilepsy syndrome	0.000323	0.0014	CcSEcCtD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—AKT1—epilepsy syndrome	0.000318	0.00362	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—JUNB—epilepsy syndrome	0.000317	0.00361	CbGpPWpGaD
Tazarotene—Pain—Pregabalin—epilepsy syndrome	0.000315	0.00137	CcSEcCtD
Tazarotene—RXRB—Regulation of Androgen receptor activity—SRC—epilepsy syndrome	0.000311	0.00354	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—NR3C1—epilepsy syndrome	0.000308	0.0035	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—KCNAB2—epilepsy syndrome	0.000306	0.00348	CbGpPWpGaD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—AKT1—epilepsy syndrome	0.000305	0.00347	CbGpPWpGaD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—AKT1—epilepsy syndrome	0.000305	0.00347	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—WARS—epilepsy syndrome	0.000298	0.00339	CbGpPWpGaD
Tazarotene—Discomfort—Topiramate—epilepsy syndrome	0.000293	0.00127	CcSEcCtD
Tazarotene—Pain—Gabapentin—epilepsy syndrome	0.000289	0.00126	CcSEcCtD
Tazarotene—Pruritus—Valproic Acid—epilepsy syndrome	0.000288	0.00125	CcSEcCtD
Tazarotene—RXRB—Gene Expression—WARS—epilepsy syndrome	0.000286	0.00325	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—WARS—epilepsy syndrome	0.000286	0.00325	CbGpPWpGaD
Tazarotene—Oedema—Topiramate—epilepsy syndrome	0.000284	0.00124	CcSEcCtD
Tazarotene—RARA—Adipogenesis—AGT—epilepsy syndrome	0.00028	0.00318	CbGpPWpGaD
Tazarotene—CYP2C8—Arachidonic acid metabolism—CYP2C19—epilepsy syndrome	0.000275	0.00313	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—BDNF—epilepsy syndrome	0.000268	0.00304	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—SIRT1—epilepsy syndrome	0.000266	0.00303	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ABCB1—epilepsy syndrome	0.000263	0.00299	CbGpPWpGaD
Tazarotene—Pruritus—Pregabalin—epilepsy syndrome	0.000261	0.00113	CcSEcCtD
Tazarotene—RARA—Adipogenesis—IL6ST—epilepsy syndrome	0.000257	0.00293	CbGpPWpGaD
Tazarotene—Rash—Valproic Acid—epilepsy syndrome	0.000257	0.00112	CcSEcCtD
Tazarotene—Dermatitis—Valproic Acid—epilepsy syndrome	0.000257	0.00112	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—BDNF—epilepsy syndrome	0.000256	0.00292	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—SIRT1—epilepsy syndrome	0.000255	0.0029	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ABCB1—epilepsy syndrome	0.000252	0.00287	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—QARS—epilepsy syndrome	0.000252	0.00286	CbGpPWpGaD
Tazarotene—Pain—Topiramate—epilepsy syndrome	0.000243	0.00106	CcSEcCtD
Tazarotene—Pruritus—Gabapentin—epilepsy syndrome	0.000239	0.00104	CcSEcCtD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2C19—epilepsy syndrome	0.000238	0.0027	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP11A1—epilepsy syndrome	0.000236	0.00269	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP2C19—epilepsy syndrome	0.000235	0.00267	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP11A1—epilepsy syndrome	0.000233	0.00265	CbGpPWpGaD
Tazarotene—Rash—Pregabalin—epilepsy syndrome	0.000232	0.00101	CcSEcCtD
Tazarotene—Dermatitis—Pregabalin—epilepsy syndrome	0.000232	0.00101	CcSEcCtD
Tazarotene—RARB—Gene Expression—QARS—epilepsy syndrome	0.000226	0.00257	CbGpPWpGaD
Tazarotene—RXRB—a6b1 and a6b4 Integrin signaling—AKT1—epilepsy syndrome	0.000221	0.00251	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—QARS—epilepsy syndrome	0.000216	0.00246	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—QARS—epilepsy syndrome	0.000216	0.00246	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2D6—epilepsy syndrome	0.000213	0.00242	CbGpPWpGaD
Tazarotene—Rash—Gabapentin—epilepsy syndrome	0.000213	0.000926	CcSEcCtD
Tazarotene—Dermatitis—Gabapentin—epilepsy syndrome	0.000213	0.000926	CcSEcCtD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP2D6—epilepsy syndrome	0.00021	0.00239	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ATM—epilepsy syndrome	0.000202	0.0023	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—EIF2B5—epilepsy syndrome	0.000201	0.00229	CbGpPWpGaD
Tazarotene—Pruritus—Topiramate—epilepsy syndrome	0.000201	0.000875	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ATM—epilepsy syndrome	0.000194	0.00221	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP2C19—epilepsy syndrome	0.000193	0.00219	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP11A1—epilepsy syndrome	0.000192	0.00218	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—JUNB—epilepsy syndrome	0.000183	0.00208	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—TFAM—epilepsy syndrome	0.000182	0.00207	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—EIF2B5—epilepsy syndrome	0.00018	0.00205	CbGpPWpGaD
Tazarotene—Rash—Topiramate—epilepsy syndrome	0.000179	0.000779	CcSEcCtD
Tazarotene—Dermatitis—Topiramate—epilepsy syndrome	0.000179	0.000779	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CASP8—epilepsy syndrome	0.000177	0.00201	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—EIF2B5—epilepsy syndrome	0.000173	0.00197	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—EIF2B5—epilepsy syndrome	0.000173	0.00197	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP2D6—epilepsy syndrome	0.000173	0.00197	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CASP8—epilepsy syndrome	0.000169	0.00193	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—JUNB—epilepsy syndrome	0.000164	0.00187	CbGpPWpGaD
Tazarotene—CYP2C8—Arachidonic acid metabolism—GPX1—epilepsy syndrome	0.000164	0.00186	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—TFAM—epilepsy syndrome	0.000163	0.00186	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—FGF2—epilepsy syndrome	0.00016	0.00181	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—JUNB—epilepsy syndrome	0.000158	0.00179	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—JUNB—epilepsy syndrome	0.000158	0.00179	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—SNRPE—epilepsy syndrome	0.000157	0.00179	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—TFAM—epilepsy syndrome	0.000156	0.00178	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—TFAM—epilepsy syndrome	0.000156	0.00178	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—FGF2—epilepsy syndrome	0.000153	0.00174	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—BCL2—epilepsy syndrome	0.000152	0.00172	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—VDR—epilepsy syndrome	0.000145	0.00165	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—BCL2—epilepsy syndrome	0.000145	0.00165	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—PTGS2—epilepsy syndrome	0.000144	0.00164	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—SNRPE—epilepsy syndrome	0.000141	0.0016	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PTGS2—epilepsy syndrome	0.000138	0.00157	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—SNRPE—epilepsy syndrome	0.000135	0.00154	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—SNRPE—epilepsy syndrome	0.000135	0.00154	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—CASP3—epilepsy syndrome	0.000134	0.00152	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—NR3C1—epilepsy syndrome	0.000131	0.00149	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—VDR—epilepsy syndrome	0.00013	0.00148	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—JUN—epilepsy syndrome	0.00013	0.00148	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—CASP3—epilepsy syndrome	0.000128	0.00146	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—TNF—epilepsy syndrome	0.000127	0.00144	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—VDR—epilepsy syndrome	0.000125	0.00142	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—VDR—epilepsy syndrome	0.000125	0.00142	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—JUN—epilepsy syndrome	0.000124	0.00141	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—FAR1—epilepsy syndrome	0.000119	0.00135	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CERS1—epilepsy syndrome	0.000119	0.00135	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—NR3C1—epilepsy syndrome	0.000117	0.00133	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—SRC—epilepsy syndrome	0.000116	0.00132	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—VEGFA—epilepsy syndrome	0.000113	0.00129	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—NR3C1—epilepsy syndrome	0.000113	0.00128	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—NR3C1—epilepsy syndrome	0.000113	0.00128	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—SRC—epilepsy syndrome	0.000112	0.00127	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—EIF2S1—epilepsy syndrome	0.00011	0.00125	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—VEGFA—epilepsy syndrome	0.000109	0.00124	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—HSPB1—epilepsy syndrome	0.000106	0.0012	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—epilepsy syndrome	0.000104	0.00119	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP2C19—epilepsy syndrome	0.000102	0.00116	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP11A1—epilepsy syndrome	0.000102	0.00116	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP2C19—epilepsy syndrome	0.000101	0.00115	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP11A1—epilepsy syndrome	0.0001	0.00114	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—EIF2S1—epilepsy syndrome	9.82e-05	0.00112	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TNF—epilepsy syndrome	9.72e-05	0.00111	CbGpPWpGaD
Tazarotene—CYP2C8—Arachidonic acid metabolism—PTGS2—epilepsy syndrome	9.64e-05	0.0011	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—HSPB1—epilepsy syndrome	9.48e-05	0.00108	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—EIF2S1—epilepsy syndrome	9.42e-05	0.00107	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—EIF2S1—epilepsy syndrome	9.42e-05	0.00107	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TNF—epilepsy syndrome	9.32e-05	0.00106	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP2D6—epilepsy syndrome	9.18e-05	0.00104	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—HSPB1—epilepsy syndrome	9.09e-05	0.00103	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—HSPB1—epilepsy syndrome	9.09e-05	0.00103	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP2D6—epilepsy syndrome	9.06e-05	0.00103	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—SLCO1A2—epilepsy syndrome	9.03e-05	0.00103	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—JUNB—epilepsy syndrome	8.82e-05	0.001	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—POMC—epilepsy syndrome	8.47e-05	0.000963	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—NEU1—epilepsy syndrome	8.26e-05	0.000939	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—HSD17B4—epilepsy syndrome	7.95e-05	0.000904	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—JUNB—epilepsy syndrome	7.91e-05	0.000899	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—JUNB—epilepsy syndrome	7.58e-05	0.000862	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—JUNB—epilepsy syndrome	7.58e-05	0.000862	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	7.24e-05	0.000823	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—ASAH1—epilepsy syndrome	7.22e-05	0.000821	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—SIRT1—epilepsy syndrome	7.1e-05	0.000807	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CA13—epilepsy syndrome	7e-05	0.000796	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—VDR—epilepsy syndrome	7e-05	0.000796	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	6.94e-05	0.000789	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—H2AFX—epilepsy syndrome	6.64e-05	0.000754	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—YWHAZ—epilepsy syndrome	6.4e-05	0.000728	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—SIRT1—epilepsy syndrome	6.37e-05	0.000724	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—NR3C1—epilepsy syndrome	6.3e-05	0.000716	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—VDR—epilepsy syndrome	6.28e-05	0.000714	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—SIRT1—epilepsy syndrome	6.11e-05	0.000694	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—SIRT1—epilepsy syndrome	6.11e-05	0.000694	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—VDR—epilepsy syndrome	6.02e-05	0.000684	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—VDR—epilepsy syndrome	6.02e-05	0.000684	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—H2AFX—epilepsy syndrome	5.95e-05	0.000677	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—YWHAZ—epilepsy syndrome	5.74e-05	0.000653	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—H2AFX—epilepsy syndrome	5.71e-05	0.000649	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—H2AFX—epilepsy syndrome	5.71e-05	0.000649	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—NR3C1—epilepsy syndrome	5.65e-05	0.000642	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—TXNRD1—epilepsy syndrome	5.64e-05	0.000641	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—YWHAZ—epilepsy syndrome	5.51e-05	0.000626	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—YWHAZ—epilepsy syndrome	5.51e-05	0.000626	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—NR3C1—epilepsy syndrome	5.42e-05	0.000616	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—NR3C1—epilepsy syndrome	5.42e-05	0.000616	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CERS1—epilepsy syndrome	5.31e-05	0.000603	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PDXK—epilepsy syndrome	5.31e-05	0.000603	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—FAR1—epilepsy syndrome	5.31e-05	0.000603	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ADK—epilepsy syndrome	5.31e-05	0.000603	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—L2HGDH—epilepsy syndrome	5.31e-05	0.000603	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GLUD1—epilepsy syndrome	5.31e-05	0.000603	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GAMT—epilepsy syndrome	4.85e-05	0.000552	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PNPO—epilepsy syndrome	4.85e-05	0.000552	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—EPM2A—epilepsy syndrome	4.85e-05	0.000552	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NHLRC1—epilepsy syndrome	4.85e-05	0.000552	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CA4—epilepsy syndrome	4.51e-05	0.000513	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—QDPR—epilepsy syndrome	4.51e-05	0.000513	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—POMC—epilepsy syndrome	4.5e-05	0.000511	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—COX3—epilepsy syndrome	4.24e-05	0.000482	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PFKL—epilepsy syndrome	4.02e-05	0.000457	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SLCO1A2—epilepsy syndrome	4.02e-05	0.000457	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CACNA2D2—epilepsy syndrome	4.02e-05	0.000457	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—KCNB1—epilepsy syndrome	4.02e-05	0.000457	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SLC6A8—epilepsy syndrome	4.02e-05	0.000457	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP2C19—epilepsy syndrome	3.93e-05	0.000447	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—epilepsy syndrome	3.91e-05	0.000444	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—UPB1—epilepsy syndrome	3.68e-05	0.000418	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NEU1—epilepsy syndrome	3.68e-05	0.000418	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ATIC—epilepsy syndrome	3.68e-05	0.000418	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HSD17B4—epilepsy syndrome	3.54e-05	0.000403	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PPP1R3C—epilepsy syndrome	3.42e-05	0.000389	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GBE1—epilepsy syndrome	3.42e-05	0.000389	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	3.34e-05	0.00038	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ASAH1—epilepsy syndrome	3.22e-05	0.000366	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—STXBP1—epilepsy syndrome	3.13e-05	0.000356	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NT5E—epilepsy syndrome	3.05e-05	0.000347	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ALAD—epilepsy syndrome	3.05e-05	0.000347	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CACNA1A—epilepsy syndrome	2.91e-05	0.000331	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ALDH7A1—epilepsy syndrome	2.91e-05	0.000331	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ST3GAL3—epilepsy syndrome	2.85e-05	0.000324	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ADSL—epilepsy syndrome	2.79e-05	0.000317	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GLUL—epilepsy syndrome	2.73e-05	0.000311	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CACNA1D—epilepsy syndrome	2.68e-05	0.000305	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TXNRD1—epilepsy syndrome	2.51e-05	0.000285	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AQP1—epilepsy syndrome	2.44e-05	0.000277	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	2.34e-05	0.000266	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—KCNJ11—epilepsy syndrome	2.2e-05	0.000251	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CHRM3—epilepsy syndrome	2.2e-05	0.000251	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	2.05e-05	0.000233	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	2.01e-05	0.000229	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—AKT1—epilepsy syndrome	1.93e-05	0.000219	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ABCG2—epilepsy syndrome	1.8e-05	0.000204	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP2C19—epilepsy syndrome	1.75e-05	0.000199	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP11A1—epilepsy syndrome	1.74e-05	0.000198	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—AKT1—epilepsy syndrome	1.73e-05	0.000197	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.73e-05	0.000196	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—AKT1—epilepsy syndrome	1.66e-05	0.000189	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—AKT1—epilepsy syndrome	1.66e-05	0.000189	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.58e-05	0.000179	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP2D6—epilepsy syndrome	1.57e-05	0.000179	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ADRA2A—epilepsy syndrome	1.5e-05	0.00017	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—BCHE—epilepsy syndrome	1.49e-05	0.000169	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SLC2A1—epilepsy syndrome	1.42e-05	0.000161	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PLCB1—epilepsy syndrome	1.4e-05	0.00016	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TH—epilepsy syndrome	1.4e-05	0.000159	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.38e-05	0.000157	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—HMOX1—epilepsy syndrome	1.17e-05	0.000133	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CAT—epilepsy syndrome	1.15e-05	0.000131	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ABCB1—epilepsy syndrome	1.12e-05	0.000127	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GPX1—epilepsy syndrome	1.04e-05	0.000119	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AGT—epilepsy syndrome	9.14e-06	0.000104	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—APOE—epilepsy syndrome	8.96e-06	0.000102	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—POMC—epilepsy syndrome	7.69e-06	8.75e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ALB—epilepsy syndrome	7.01e-06	7.97e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PTGS2—epilepsy syndrome	6.14e-06	6.98e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—AKT1—epilepsy syndrome	3.08e-06	3.51e-05	CbGpPWpGaD
